September 2021 RESULTS OF COURT MEETING AND GENERAL MEETING On 20 August 2021, Tiziana Life Sciences Plc (" Old Tiziana ") announced that it has formally commenced its strategic plan to change it

OF COURT MEETING AND GENERAL MEETING

20 August 2021, Tiziana Life Sciences Plc ("Old Tiziana") announced that it has formally commenced its strategic plan

to change its corporate structure by establishing Tiziana Life Sciences Ltd ("New Tiziana"), a Bermuda-incorporated

company, as the ultimate parent company of the of the Tiziana Group, to be effected by means of a scheme of arrangement under Part 26

of the Companies Act 2006 (the "Scheme").

of directors of Old Tiziana (the "Board") is pleased to announce that at the Court Meeting and the General Meeting

held earlier today in connection with the Scheme:

of the resolutions passed are set out in the notices of the Court Meeting and the General Meeting contained in Parts VIII and IX (respectively)

of the scheme document published and posted to Old Tiziana shareholders on 3 September 2021 (the "Scheme Document"). Full

details of the Scheme are set out in the Scheme Document.

total number of ordinary shares in Old Tiziana in issue at the Voting Record Time (being 6.00 p.m. on 23 September 2021) was 194,612,289

ordinary shares of 3 pence each. As at the Voting Record Time, Tiziana did not hold any Old Tiziana shares in treasury.

summary of the voting results in relation to the Court Meeting and the General Meeting is set out below.

Results of the Court Meeting

the Court Meeting convened in accordance with an order of the Court dated 26 August 2021, a majority in number of the Scheme Shareholders

who voted (either in person or by proxy) and who together represented 99.11 per cent. in value of the Scheme Shares held by those Scheme

Shareholders, voted by way of poll in favour of the resolution to approve the Scheme. Each Scheme Shareholder, present in person or by

proxy, was entitled to one vote for each Scheme Share held at the Voting Record Time.

the resolution to approve the Scheme was duly passed. Details of the votes cast by Scheme Shareholders were as follows:

Results of the General Meeting

the General Meeting, the resolutions needed to authorise the directors of Tiziana to take all such action as they consider necessary or

appropriate for carrying the Scheme into effect, to approve associated amendments to the Articles of Association and, conditional upon

and subject to the Scheme having become effective, approve the New Tiziana Share Option Scheme and authorise the directors of New Tiziana

to implement the scheme were duly passed, on a poll, by the requisite majority of Tiziana Shareholders. Each Tiziana Shareholder, present

in person or by proxy, was entitled to one vote for each Tiziana Share held at the Voting Record Time.

of the votes cast by Tiziana Shareholders were as follows:

vote withheld is not a vote in law and was not counted in the calculation of the proportion of the votes cast either "For" or

"Against" the relevant Special Resolution. Any proxy appointments which gave discretion to the Chairman have been included in

the vote "For" total.

figures included in the tables above have been subjected to rounding adjustments. Accordingly, figures shown and presented in different

columns may vary slightly from the full arithmetic aggregation of those figures.

Scheme remains subject to sanction by the Court at the Court Hearing, the delivery of a copy of the Court Order to the Registrar of Companies

and the satisfaction of the other conditions set out in Paragraph 3 of Part II of the Scheme Document. The Court Hearing will be held

is intended that, prior to the Scheme becoming Effective, applications will be made to the FCA and the London Stock Exchange to cancel

the admission of Old Tiziana shares on the Standard Segment of the Official List and to trading on the London Stock Exchange's Main Market

for listed securities respectively.

expected timetable of principal events is as follows:

Timetable of Principal Events

the purposes of UK MAR, the person responsible for arranging for the release of this announcement on behalf of Tiziana is Dr Kunwar Shailubhai,

Chief Executive Officer.

FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO

WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

ANNOUNCEMENT CONTAINS INSIDE INFORMATION

further information please contact:

Keeren Shah, Finance Director: +44

Tiziana Life Sciences

Life Sciences plc is a dual listed (NASDAQ: TLSA & UK LSE: TILS) biotechnology company that focuses on the discovery and development

of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to Milciclib, the Company will

be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn's Disease and nasally administered Foralumab for progressive

multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody ("mAb") in clinical development in the world.

This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple

sclerosis, type-1 diabetes ("T1D"), inflammatory bowel disease ("IBD"), psoriasis and rheumatoid arthritis, where

modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor ("IL6R")

mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.